The key purpose of these Blending Team products is to instruct treatment providers about a unique, 13-day buprenorphine intervention for opioid dependent patients. To test its effectiveness, he NIDA CTN protocol compared this 13-day buprenorphine taper intervention to an alternative treatment (clonidine detoxification) in both inpatient and outpatient settings. In contrast with the clonidine treatment group, patients who received buprenorphine provided more opioid negative urine samples upon completion of the intervention.

The Short-term Opioid Withdawal Using Buprenorphine (Bup Detox) Blending Team designed a training package to instruct treatment providers on the administration of a unique,13-day Buprenorphine taper intervention for opioid dependent patients. Research conducted in both inpatient and outpatient settings by the NIDA Clinical Trials Network demonstrated that, in contrast with the clonidine treatment group, patients receiving Buprenorphine provided more opioid-negative urine samples upon completion of the intervention. This training assumes some basic prior information about what Buprenorphine is and how it is used.

-4 hour classroom training providing instruction on using Buprenorphine for opioid dependent patients
•PowerPoint presentation
•Brochure
•Research articles